LifeSci Advisors Initiates Coverage of Oramed Pharmaceuticals
March 20 2014 - 9:30AM
Marketwired
LifeSci Advisors Initiates Coverage of Oramed Pharmaceuticals
NEW YORK, NY--(Marketwired - Mar 20, 2014) - LifeSci
Advisors, LLC and Oramed Pharmaceuticals (NASDAQ: ORMP)
- Oramed's Oral Insulin Development Program is in Phase II
for the Treatment of Diabetes
- Report Available for Download at
http://www.lifesciadvisors.com/clients/oramed/
LifeSci Advisors, LLC, a leading provider of investment research
and investor relations services in the life sciences sector, today
announced that it has initiated coverage of Oramed Pharmaceuticals
(NASDAQ: ORMP), a pharmaceutical company developing a platform
technology for the oral delivery of proteins and peptides. The
Company's proprietary protein oral delivery (PODâ„¢) technology
protects proteins during gastrointestinal transport and facilitates
absorption into the bloodstream. The Company's lead candidate is
ORMD-0801, an oral insulin product that is being tested in
different populations of diabetes patients. Oramed is also
developing ORMD-0901, an oral version of the GLP-1 agonist
exenatide. Oral insulin delivery is similar to pancreatic
insulin secretion because after absorption in the intestine it goes
directly to the liver, more closely mimicking the natural process
than insulin injections. Two Phase II trials with ORMD-0801
are expected to launch in 2014.
"Oramed is leveraging its technology platform to develop an oral
insulin product for diabetes," said Andrew I. McDonald, Ph.D.,
Founding Partner at LifeSci Advisors. "If the protein oral delivery
technology platform is shown to be a safe and effective way to
deliver insulin, it has the potential to improve compliance and
quality of life by reducing injections for diabetes patients."
In January 2014, Oramed announced positive topline results from
a randomized, placebo-controlled Phase IIa trial of ORMD-0801 in
type 2 diabetics. The results indicated that ORMD-0801 was safe and
well tolerated with no serious adverse events (AEs) in the study.
Oramed is scheduled to present more detailed data from the trial at
the 2014 Diabetes Summit on April 24th in Cambridge, MA. Oramed is
also expanding the application of their PODâ„¢ technology for oral
delivery of the GLP-1 receptor agonist exenatide. The Company is
planning to launch an ex-US Phase Ib trial in the second quarter of
2014, while concurrently completing 90-day preclinical toxicology
studies intended to pave the way to commencement of a US-based
Phase IIb trial that is expected to start in the first half
2015.
In a 41 page Initiation Report by LifeSci Advisors, we explain
the development path plus detailed clinical and preclinical data
for Oramed's oral insulin and oral exenatide programs. The report
details Oramed's clinical development strategy for type 1 and type
2 diabetes mellitus. We examine the treatment landscape and
competition for insulin, and critically examine competing products
and development programs.
Dr. McDonald's full Initiation Report is available to download
at no cost at the LifeSci Advisors website,
www.lifesciadvisors.com. In addition to this Initiation
Report, LifeSci Advisors will also provide ongoing coverage and
event-based research updates on the Company as developments
occur.
The LifeSci Advisors research team is led by Dr. Andrew I.
McDonald, an industry veteran with more than 15 years of healthcare
industry experience. Prior to co-founding LSA, Dr. McDonald
was the Senior Biotechnology Analyst at Great Point Partners, a
leading health care investment firm with over $500 million under
management. Before Great Point, he was Co-Head of Healthcare
Research and Lead Biotechnology Analyst at ThinkEquity Partners, a
boutique investment banking firm focused on growth
companies. Dr. McDonald holds a Ph.D. in organic chemistry
from the University of California, Irvine, and, earlier in his
career, worked as a medicinal chemist at both Pfizer and
Cytokinetics.
About LifeSci
Advisors:
LifeSci Advisors (LSA) is a leading research firm and
communications consultancy dedicated to the life sciences industry.
The firm provides strategic counsel, customized marketing
communications, comprehensive research reports and investor
relations services to companies that specialize in the discovery,
development and commercialization of drugs, drug delivery systems,
medical devices and diagnostics. To learn more about LSA,
visit the company's website, www.lifesciadvisors.com.
Important
Disclosures:
The research report described in this press release is not
intended as an offering, recommendation, or a solicitation of an
offer to buy or sell securities. The securities discussed in
LSA research reports may be unsuitable for some investors depending
on their specific investment objectives, financial status, risk
profile, or particular needs. Investors should consider LSA reports
as only a single factor in making their investment decisions and
should not rely solely on these reports in evaluating whether or
not to buy or sell the securities of the subject
company. LifeSci Advisors has been compensated by the company
that is the subject of the report described and future research
reports, investor relations services, and general consulting
services. Please read each report's full disclosures and analyst
background on the LSA website, www.lifesciadvisors.com, before
investing. LifeSci Advisors is not a registered investment
adviser or broker-dealer.
Forward-looking
statements: This press release contains forward-looking
statements subject to risks and uncertainties that could cause
actual results to differ materially from those projected. These
forward-looking statements represent LSA's judgment as of the date
of this release. LifeSci Advisors disclaims, however, any intent or
obligation to update these forward-looking statements.
Media Contact: Michael Rice Phone: (646) 597-6979 Email:
mrice@lifesciadvisors.com
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Sep 2023 to Sep 2024